



Oncogenic Signaling Pathways in Cancer

Guest Editor:

Prof. Dr. Bu-Miin Huang

Department of Cell Biology and
Anatomy, College of Medicine,
National Cheng Kung University,
Tainan, Taiwan

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

This Special Issue, "*Oncogenic Signaling Pathways in Cancer*", focuses on the oncogenic roles of different signaling pathways among cancers. Signaling pathways are essential to modulate various intracellular metabolic steps for normal physiological functions in cells. However, an abnormality of any signaling pathway triggering irregular cell proliferation could result in cancer development and progression. Thus, revealing the mechanism of oncogenic signaling pathway in cancer is important for therapeutic purposes. Accordingly, all investigations of signaling pathway(s), single or multiple and/or with crosstalk, at the cellular, molecular and genetic levels related to cancer events plus drug and/or molecule designs for cancer treatments are graciously invited, in the form of original research or review articles covering this significant and fast-growing field of biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)